52 related articles for article (PubMed ID: 20528318)
21. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
[TBL] [Abstract][Full Text] [Related]
22. Systematic review of cost-effectiveness analyses of treatments for psoriasis.
Zhang W; Islam N; Ma C; Anis AH
Pharmacoeconomics; 2015 Apr; 33(4):327-40. PubMed ID: 25475964
[TBL] [Abstract][Full Text] [Related]
23. Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.
Villacorta R; Hay JW; Messali A
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):545-58. PubMed ID: 24820676
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
25. A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.
Colombo GL; Di Matteo S; Peris K; Fargnoli MC; Esposito M; Mazzotta A; Chimenti S
Clinicoecon Outcomes Res; 2009; 1():53-9. PubMed ID: 21935307
[TBL] [Abstract][Full Text] [Related]
26. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
28. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.
Scheinfeld N; Parish D
Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):545-57. PubMed ID: 20528318
[TBL] [Abstract][Full Text] [Related]
30. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
31. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
Staidle JP; Dabade TS; Feldman SR
Expert Opin Pharmacother; 2011 Sep; 12(13):2041-54. PubMed ID: 21736530
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
